
Emavusertib
CAS No. 1801344-14-8
Emavusertib( CA-4948 )
Catalog No. M23815 CAS No. 1801344-14-8
Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | In Stock |
![]() ![]() |
5MG | 63 | In Stock |
![]() ![]() |
10MG | 80 | In Stock |
![]() ![]() |
25MG | 160 | In Stock |
![]() ![]() |
50MG | 295 | In Stock |
![]() ![]() |
100MG | 507 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameEmavusertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
In Vitro——
-
In VivoAnimal Model:Mice bearing OCI-LY10 tumorsDosage:25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)Administration:Orally, once daily or twice daily, for 14 consecutive days Result:Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.
-
SynonymsCA-4948
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT3|IRAK4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1801344-14-8
-
Formula Weight491.5
-
Molecular FormulaC24H25N7O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:27.78 mg/mL (56.52 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
-
SMILESCC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.
molnova catalog



related products
-
AXL-IN-13
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
-
FLT3-IN-10
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).
-
FLT3-IN-2
FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM.